Repare Therapeutics Inc. Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020
Revenue:
Collaboration agreements
Operating expenses:
Research and development, net of tax credits
General and administrative
Restructuring
Total operating expenses
Loss from operations
Other income (expense), net
Realized and unrealized loss on foreign exchange
Interest income
Other expense, net
Total other income, net
Loss before income taxes
Income tax (expense) benefit
Net loss and comprehensive loss
Net loss per share attributable to common shareholders—basic and diluted
Weighted-average common shares outstanding—basic and diluted
Net loss
Other comprehensive income:
Unrealized gain on available-for-sale marketable securities
Total other comprehensive income
Comprehensive loss
Net loss per share attributable to common shareholders--basic
Net loss per share attributable to common shareholders--diluted
Weighted-average common shares outstanding-basic
Weighted-average common shares outstanding-diluted

Comments